Lite Strategy, Inc. (LITS) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
45/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseLITS / S&P -20.69% / 15.20% |
LoseLITS / S&P LITS unavailable / 15.00% |
LoseLITS / S&P LITS unavailable / 50.40% |
| 2026-Q10/3 |
LoseLITS / S&P -12.12% / -4.33% |
LoseLITS / S&P LITS unavailable / 11.30% |
LoseLITS / S&P -57.89% / 27.70% |
| 2025-Q40/3 |
LoseLITS / S&P -45.45% / 2.65% |
LoseLITS / S&P LITS unavailable / 9.00% |
LoseLITS / S&P -69.81% / 13.40% |
| 2025-Q30/3 |
LoseLITS / S&P -2.02% / 8.12% |
LoseLITS / S&P LITS unavailable / 4.61% |
LoseLITS / S&P -81.26% / 13.45% |
| 2025-Q21/3 |
WinLITS / S&P 12.79% / 10.94% |
LoseLITS / S&P -100.00% / 4.83% |
LoseLITS / S&P -189.51% / 10.63% |
| 2025-Q10/3 |
LoseLITS / S&P -10.98% / -4.27% |
LoseLITS / S&P -100.00% / 4.98% |
LoseLITS / S&P -221.17% / 10.57% |
| 2024-Q40/3 |
LoseLITS / S&P -13.68% / 2.41% |
LoseLITS / S&P -100.00% / 5.25% |
LoseLITS / S&P -292.93% / 6.15% |
| 2024-Q30/3 |
LoseLITS / S&P -2.06% / 5.89% |
LoseLITS / S&P -100.00% / 5.89% |
LoseLITS / S&P -213.29% / 6.11% |
| 2024-Q21/3 |
LoseLITS / S&P -27.25% / 4.28% |
WinLITS / S&P 33.76% / 5.38% |
LoseLITS / S&P -155.86% / 5.12% |
| 2024-Q11/3 |
LoseLITS / S&P -31.03% / 10.56% |
WinLITS / S&P 13.58% / 5.71% |
LoseLITS / S&P -169.01% / 5.59% |
| 2023-Q41/3 |
LoseLITS / S&P 6.51% / 11.69% |
WinLITS / S&P 16.10% / 6.81% |
LoseLITS / S&P -163.60% / 7.78% |
| 2023-Q32/3 |
WinLITS / S&P 6.53% / -3.27% |
WinLITS / S&P 152.90% / 7.52% |
LoseLITS / S&P -197.17% / -5.03% |
| 2023-Q23/3 |
WinLITS / S&P 43.04% / 8.74% |
WinLITS / S&P 19.95% / 9.50% |
WinLITS / S&P 18.32% / -8.57% |
| 2023-Q12/3 |
LoseLITS / S&P -4.17% / 7.50% |
WinLITS / S&P 59.98% / 10.77% |
WinLITS / S&P 222.73% / -15.69% |
| 2022-Q42/3 |
LoseLITS / S&P -38.46% / 7.56% |
WinLITS / S&P 78.01% / 11.88% |
WinLITS / S&P 586.76% / -17.99% |
| 2022-Q32/3 |
LoseLITS / S&P -36.07% / -4.88% |
WinLITS / S&P 28.27% / 13.47% |
WinLITS / S&P 807.14% / -1.41% |
| 2022-Q23/3 |
WinLITS / S&P 1.67% / -16.10% |
WinLITS / S&P 42.48% / 13.71% |
WinLITS / S&P 521.54% / 11.04% |
| 2022-Q11/3 |
LoseLITS / S&P -77.53% / -4.60% |
LoseLITS / S&P -19.18% / 15.97% |
WinLITS / S&P 144.44% / 42.23% |
| 2021-Q40/3 |
LoseLITS / S&P -3.26% / 11.03% |
LoseLITS / S&P -8.91% / 15.00% |
LoseLITS / S&P 28.30% / 96.40% |
| 2021-Q30/3 |
LoseLITS / S&P -3.16% / 0.58% |
LoseLITS / S&P 6.75% / 10.77% |
LoseLITS / S&P 11.11% / 69.42% |
| 2021-Q20/3 |
LoseLITS / S&P -16.91% / 8.55% |
LoseLITS / S&P 2.91% / 6.58% |
LoseLITS / S&P 20.37% / 51.81% |
| 2021-Q13/3 |
WinLITS / S&P 29.92% / 6.17% |
WinLITS / S&P 901.48% / -1.06% |
WinLITS / S&P 46.94% / 7.39% |
| 2020-Q42/3 |
LoseLITS / S&P -15.38% / 12.15% |
WinLITS / S&P 749.30% / -3.72% |
WinLITS / S&P -23.19% / -33.42% |
| 2020-Q32/3 |
LoseLITS / S&P -24.46% / 8.93% |
WinLITS / S&P 445.00% / -2.04% |
WinLITS / S&P 8.62% / -27.10% |
| 2020-Q22/3 |
WinLITS / S&P 156.52% / 20.54% |
WinLITS / S&P 464.72% / -0.46% |
LoseLITS / S&P -28.00% / -27.11% |
| 2020-Q11/3 |
LoseLITS / S&P -35.08% / -19.60% |
WinLITS / S&P 4.75% / 3.47% |
LoseLITS / S&P -51.49% / -14.75% |
| 2019-Q42/3 |
WinLITS / S&P 47.62% / 9.07% |
WinLITS / S&P 29.20% / 5.36% |
LoseLITS / S&P -25.81% / 2.99% |
| 2019-Q31/3 |
LoseLITS / S&P -32.80% / 1.70% |
WinLITS / S&P 205.64% / 5.02% |
LoseLITS / S&P -38.30% / 0.21% |
| 2019-Q21/3 |
LoseLITS / S&P -18.57% / 4.30% |
WinLITS / S&P 203.02% / 6.64% |
LoseLITS / S&P -22.68% / 8.65% |
| 2019-Q13/3 |
WinLITS / S&P 16.29% / 13.65% |
WinLITS / S&P 184.50% / 8.12% |
WinLITS / S&P 48.53% / 14.29% |
| 2018-Q41/3 |
LoseLITS / S&P -38.75% / -13.52% |
LoseLITS / S&P -37.14% / 9.05% |
WinLITS / S&P 72.22% / 18.23% |
| 2018-Q32/3 |
WinLITS / S&P 9.39% / 7.71% |
LoseLITS / S&P -91.86% / 10.21% |
WinLITS / S&P 1466.67% / 19.06% |
| 2018-Q21/3 |
WinLITS / S&P 90.34% / 3.43% |
LoseLITS / S&P -93.02% / 9.03% |
LoseLITS / S&P -1716.67% / 14.46% |
| 2018-Q10/3 |
LoseLITS / S&P -1.43% / -0.76% |
LoseLITS / S&P LITS unavailable / 7.68% |
LoseLITS / S&P -6900.00% / 12.46% |
| 2017-Q41/3 |
LoseLITS / S&P -21.64% / 6.64% |
LoseLITS / S&P LITS unavailable / 7.03% |
WinLITS / S&P 315.38% / 13.82% |
| 2017-Q31/3 |
WinLITS / S&P 12.13% / 4.48% |
LoseLITS / S&P LITS unavailable / 5.68% |
LoseLITS / S&P -90.00% / 17.57% |
| 2017-Q21/3 |
WinLITS / S&P 47.53% / 3.09% |
LoseLITS / S&P LITS unavailable / 4.83% |
LoseLITS / S&P LITS unavailable / 17.74% |
| 2017-Q11/3 |
WinLITS / S&P 12.50% / 6.07% |
LoseLITS / S&P LITS unavailable / 3.67% |
LoseLITS / S&P LITS unavailable / 13.32% |
| 2016-Q40/3 |
LoseLITS / S&P -18.18% / 3.82% |
LoseLITS / S&P LITS unavailable / 2.09% |
LoseLITS / S&P LITS unavailable / 7.05% |
| 2016-Q31/3 |
WinLITS / S&P 29.41% / 3.85% |
LoseLITS / S&P LITS unavailable / 0.20% |
LoseLITS / S&P LITS unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | LITS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -79.42% | 20.78% |
| Annualized return | -79.42% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | LITS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.73% | 83.14% |
| Annualized return | -53.08% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | LITS total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.30% | 319.30% |
| Annualized return | -28.09% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |